EU H2020 Project "RHYP (A new hope for early gonarthrosis treatment using a biotechnological..)": description, partecipants, costs and EC-fundings

#	Pagina
attuale pagina	/open-h2020/projects/211109/index.html
-1	/open-h2020/projects/217451/index.html
-2	/open-h2020/projects/194469/index.html

RHYP project word cloud

Explore the words cloud of the RHYP project. It provides you a very rough idea of what is the project "RHYP" about.

organization 75 hyaluronic drug human sme gonarthrosis global stop proliferation symptomatic restore younger athletes successful joint ambition gap people surgery tackle batch disruptive candidate countries rhyp obese curative gmp smeinst treatment pushing drawback acid function conduct licensees huge market replacement vivo reg commercialization worldwide instrument conditioning o3 economic articulation administration 03 health burden therapeutic total disease 2017 slow degradation contribution viscosupplementation suffer clinical plug chondrocytes launching partnership proof cartilage months mainly trial sustain social competitive ec 24 manufacturing painless feasibility clinics action responding activation stage world thanks syringes 2014 molecules mode mrd prepare local knee treatments 450 ga moderate price 2016 first degenerative 5 progression 50 previously trl vitro requested trials injection

Project "RHYP" data sheet

The following table provides information about the project.

Coordinator	REGULAXIS Organization address address: 102 AVENUE GASTON ROUSSEL city: ROMAINVILLE postcode: 93230 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	France [FR]
Project website	http://regulaxis.com/
Total cost	3˙008˙500 €
EC max contribution	2˙105˙950 € (70%)
Programme	1. H2020-EU.2.1.4. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Biotechnology) 2. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
Code Call	H2020-SMEINST-2-2016-2017
Funding Scheme	SME-2
Starting year	2017
Duration (year-month-day)	from 2017-06-01 to 2020-11-30

#	participants	country	role	EC contrib. [€]
1	REGULAXIS	FR (ROMAINVILLE)	coordinator	2˙105˙950.00

REGULAXIS

FR (ROMAINVILLE)

coordinator

2˙105˙950.00

Project objective

The aim of RHYP is to sustain the commercialization of a new promising therapeutic product (REG-O3) to restore the joint function for the treatment of early and moderate gonarthrosis (GA). GA is a degenerative knee joint disease that represents a huge social and economic burden worldwide. According to the World Health Organization, more than 5% of people over 40 and 50% of people over 75 years suffer specifically from GA in developed countries. It affects also a growing number of younger people as athletes and obese people, among others. There are currently no therapeutic molecules on the market for the treatment of early GA to slow down or stop disease progression and avoid surgery joint replacement. Available treatments for this disease stage are mainly symptomatic, such as the widely use injection of hyaluronic acid (HA) in articulation (viscosupplementation – Global market €1.5 Mrd in 2014). RHYP’s ambition is to tackle this current drawback by pushing forward its drug candidate REG-O3 into clinics to propose a disruptive and long-term treatment (curative and symptomatic action) using a painless local administration mode at a competitive price (€450 for total treatment is estimated). The selected lead REG-O3 activity proof of concept on chondrocytes proliferation activation to slow down cartilage degradation was previously established in vitro and in vivo. Following successful feasibility studies conducted thanks to the European commission (EC) through the Phase 1 of the SME Instrument, RHYP is now responding to the topic “SMEInst-03-2016-2017” in phase 2. RHYP is now aiming, during this 24 months’ project with a EC requested contribution of €2,1 M, to plug the gap from TRL 6 to TRL 9 by launching REG-O3 GMP batch manufacturing and syringes conditioning to conduct First-in-Human clinical trial. The project objective is also to prepare future partnership with identified potential licensees to conduct Clinical trials in Phase III and drug commercialization.

Deliverables

List of deliverables.
Ethical protocols reports and authorization approval copies	Documents, reports	2020-04-16 13:45:11
Report to present RHYP corporate identity and first leaflet and promotion material models	Documents, reports	2020-01-21 15:58:55

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "RHYP" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "RHYP" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.1.4.;H2020-EU.2.3.1.)